“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...

--Today, Annexon, Inc., a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced that ...

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at ...

Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once ...

Broome CM, Röth A, Kuter DJ, et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia. Blood Adv. Published online August 16, 2022 ...

The lectin pathway is homologous to the classical pathway, but with the opsonin, mannose-binding lectin (MBL) and ficolins, instead of C1q. The FDA has now approved seven indications for ...

“It is postulated that our patient had [the] complement-mediated subtype of wAIHA, and activation of the classical complement pathway and its eventual inhibition at the level of C1s by ...

Sutimlimab is an immunoglobulin G subclass 4 (IgG4) monoclonal antibody that inhibits the classical complement pathway and specifically binds to complement protein component 1. This inhibition ...

Antibodies potentially contributing to classical complement activation in six-month PASC patients were measured by phage immunoprecipitation sequencing for 87,890 epitopes in 57 patients during ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...